Michael J. Hogan's research works | The Children's Hospital of Philadelphia, PA (CHOP) and other places
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery - ScienceDirect
Nanotechnology for COVID-19: Therapeutics and Vaccine Research. - Abstract - Europe PMC
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
mRNA vaccines - a new era in vaccinology. - Abstract - Europe PMC
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
Nanomaterials | Free Full-Text | Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives | HTML
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-C
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Moncef Slaoui - Wikipedia
FDA approves potential COVID-19 vaccine by Moderna for second-stage study - UPI.com
Moderna's coronavirus vaccine shows encouraging early results - The Washington Post
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
COVID-19 tracker: Regeneron's antibody cocktail hit by safety concerns; Novo's Rybelsus emerging from pandemic slump | FiercePharma
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses: Molecular Therapy
mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discovery
PDF) Modified mRNA Vaccines Protect against Zika Virus Infection
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness | bioRxiv
Moderna's coronavirus vaccine trial is fully enrolled, 37 percent of participants are minorities - The Washington Post
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery - ScienceDirect
